DBV Technologies S.A Current Ratio 2015-2021 | DBVT

DBV Technologies S.A current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
DBV Technologies S.A Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.14B $0.04B 3.58
2021-03-31 $0.16B $0.04B 4.12
2020-12-31 $0.21B $0.05B 3.93
2020-06-30 $0.26B $0.06B 4.28
2020-03-31 $0.00B 0.00
2019-12-31 $0.21B $0.05B 3.79
2019-06-30 $0.16B $0.05B 3.00
2018-12-31 $0.17B $0.05B 3.34
2018-06-30 $0.28B $0.04B 6.59
2017-12-31 $0.18B $0.04B 4.37
2017-06-30 $0.24B $0.04B 6.75
2016-12-31 $0.30B $0.03B 9.39
2015-12-31 $0.37B $0.02B 20.90
2015-06-30 $0.13B $0.01B 14.50
2014-12-31 $0.16B $0.01B 21.90
2014-06-30 $0.05B $0.01B 6.51
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.607B $0.011B
DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76